Back to Results
First PageMeta Content
Clinical research / Food and Drug Administration / Pharmaceutical industry / Epidemiology / Drug discovery / Biomarker / Clinical trial / Imaging biomarker / Critical Path Institute / Medicine / Pharmacology / Pharmaceutical sciences


ICON Selected by the FDA to Develop New Patient-Reported Outcome Measure for Hospital-Acquired Bacterial Pneumonia Trials New PRO measure being developed in conjunction with the FNIH Biomarkers Consortium Dublin, Ireland
Add to Reading List

Document Date: 2014-11-06 11:19:26


Open Document

File Size: 413,35 KB

Share Result on Facebook

City

Dublin / /

Company

Biomarkers Consortium / Bacterial Pneumonia Trials New PRO / ICON plc / /

Country

United States / Ireland / /

/

Event

Business Partnership / /

Facility

National Institute of Allergy / /

IndustryTerm

biotechnology / outsourced development services / pharmaceutical / /

MedicalCondition

hospital-acquired bacterial pneumonia / disease / common hospital-acquired infection / diseases / infection / /

MedicalTreatment

antibiotics / /

Organization

Congress / National Institute of Allergy and Infectious Diseases / National Institute of Health / Foundation for the National Institutes of Health / FDA / Infectious Diseases Society of America / U.S. Securities and Exchange Commission / US Food & Drug Administration / /

Person

Elizabeth Thiele / Rebecca Power Weber Shandwick / /

/

Position

Governor / President / ICON Commercialisation & Outcomes / /

Technology

biotechnology / drug development / /

URL

www.fnih.org / www.iconplc.com / http /

SocialTag